國立高雄大學圖資館 |

Plant-based therapeutics.cannabis sativa /Volume 1

Record Type:	Electronic resources : Monograph/item
Title/Author:	Plant-based therapeutics.by Ivan A. Ross.
Reminder of title:	cannabis sativa /
Author:	Ross, Ivan A.
Published:	Cham :Springer International Publishing :2023.
Description:	xxi, 657 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	CannabisTherapeutic use.
Online resource:	https://doi.org/10.1007/978-3-031-35155-6
ISBN:	9783031351556$q(electronic bk.)

Plant-based therapeutics.cannabis sativa /Volume 1
Ross, Ivan A.

Plant-based therapeutics.cannabis sativa /Volume 1[electronic resource] :by Ivan A. Ross. - Cham :Springer International Publishing :2023. - xxi, 657 p. :ill., digital ;24 cm.

Chapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.

By examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions.

ISBN: 9783031351556$q(electronic bk.)

Standard No.: 10.1007/978-3-031-35155-6doiSubjects--Topical Terms:

846313
Cannabis
--Therapeutic use.

LC Class. No.: RM666.C266

Dewey Class. No.: 615.7827

Plant-based therapeutics.cannabis sativa /Volume 1
LDR:03423nmm a2200325 a 4500 001 647313
003 DE-He213
005 20230808023038.0
006 m d
007 cr nn 008maaau
008 240116s2023 sz s 0 eng d
020 $a 9783031351556$q(electronic bk.)
020 $a 9783031351549$q(paper)
024 7 $a 10.1007/978-3-031-35155-6 $2 doi
035 $a 978-3-031-35155-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RM666.C266
072 7 $a PST $2 bicssc
072 7 $a SCI011000 $2 bisacsh
072 7 $a PST $2 thema
082 0 4 $a 615.7827 $2 23
090 $a RM666.C266 $b R824 2023
100 1 $a Ross, Ivan A. $3 273800
245 1 0 $a Plant-based therapeutics. $n Volume 1 $h [electronic resource] : $b cannabis sativa / $c by Ivan A. Ross.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xxi, 657 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.
520 $a By examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions.
650 0 $a Cannabis $x Therapeutic use. $3 846313
650 0 $a Medicinal plants. $3 210655
650 1 4 $a Plant Science. $3 911813
650 2 4 $a Complementary and Alternative Medicine. $3 913063
650 2 4 $a Pharmacology. $3 218135
650 2 4 $a Medicinal Chemistry. $3 275183
650 2 4 $a Physiology. $3 192980
650 2 4 $a Agriculture. $3 274257
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-35155-6
950 $a Biomedical and Life Sciences (SpringerNature-11642)